ERBB2 and breast cancer: In a recent Ontario-based study regarding BC screening patterns, triple negative and HER2+ BCs were diagnosed at a more advanced stage than HR+/HER2- tumors, possibly owing to faster growth rates rather than a relative inability to detect them in screening [21].